Jeffrey Wolf, MD, on Emerging T-Cell Engagers and Their Impact in Multiple Myeloma

Video

The interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.

Jeffrey Wolf, MD, of the University of California San Francisco, spoke with CancerNetwork® on the emergence of T-cCell engagers at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition and their potential to phase out multiple myeloma drugs with limited response rates.

Transcription:

Last year, it was all about CAR [chimeric antigen receptor] T-cell [therapies]. This year, it’s all about T-cell engagers [TCEs]. It’s exciting that we have more than 1 target; that is, more than just BCMA [B-cell maturation antigen] as a target for CAR T. For TCEs, we have at least 2 more targets.

The thing is that if… CAR Ts, maybe the next generation of CAR T gives us more than a year of control, and if T-cell engagers continue to look so exciting, I’m not sure that drugs that [with] just give us 3 or 4 months, 30% response rates and 3 or 4 months of control are going to be able to compete. I really think that myeloma is going to get to a point where our first-line therapies are going to get us 5 or 7 years [of control] and then our second-line therapies, whether they’re CAR Ts or TCEs, can give us maybe 2, 3, or 4 more years. Now we’re out a decade and by then, we’re probably going to have newer therapies [with] second-, third-, and fourth generation CAR T or BiTEs [bispecific T-cell engagers]. I have to say that I’m becoming less interested in the drugs that just give us 30% responses for 3 months.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content